| DC48175 |
NLRP3 modulators 1 |
NLRP3 modulators 1 is the potent modulator of NLRP3. NLRP3 modulators 1 agonizes or partially agonizes NLRP3 that are useful for researching a condition, disease or disorder in which a decrease in LRP3 activity contributes to the pathology (extracted from patent WO2017184746A1, compound 107). |
|
| DC48176 |
PD-L1-IN-1 |
PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells. |
|
| DC48177 |
ARB-272572 |
ARB-272572 is a potent small-molecule PD-L1 inhibitor with an IC50 value of 400 pM. |
|
| DC48178 |
SN-008 |
SN-008, a less active SN-011 analog, can be used as a negative control. |
|
| DC48179 |
Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH |
Tri(TLR4-IN-C34-PEG2-amide-PEG1)-amide-C3-COOH is a linker that incorporates TLR4 inhibitor TLR4-IN-C34. TLR4-IN-C34 inhibits TLR4 in enterocytes and macrophages, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis. |
|
| DC48180 |
GSK1795091 |
GSK1795091 (CRX-601), an immunologic stimulator, is a synthetic TLR4 agonist. Antitumor activity. GSK1795091 can be used as a vaccine adjuvant to enhance both mucosal and systemic immunity to influenza virus vaccines. |
|
| DC48181 |
Polvitolimod |
Polvitolimod is a TLR7 agonist for treatment of cancer and infectious disease. |
|
| DC48182 |
Poly(I:C) |
Poly(I:C) is a synthetic double-stranded RNA (dsRNA), which is a Toll-like receptor 3 (TLR3) agonist. Poly(I:C) present in some viruses, and is therefore commonly used to model the actions of extracellular dsRNA. |
|
| DC48183 |
Ruzotolimod |
Ruzotolimod is the agonist of TLR7. Ruzotolimod has the potential for the research of HBV, COVID-19 or SARS-CoV-2 infection (extracted from patent WO2021130195A1). |
|
| DC48184 |
TLR7/8 agonist 4 TFA |
TLR7/8 agonist 4 TFA (compound 41) is a potent TLR7/8 agonist. TLR7/8 agonist 4 has anti-cancer activity. |
|
| DC48417 |
IL-17A inhibitor 2 |
IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis. |
|
| DC48426 |
Rafutrombopag |
Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A. |
|
| DC48474 |
L-Arginine-13C6,15N4 hydrochloride |
L-Arginine-13C6,15N4 ((S)-(+)-Arginine-13C6,15N4) hydrochloride is the 13C- and 15N-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. |
|
| DC48475 |
L-Arginine-13C6 hydrochloride |
L-Arginine-13C6 ((S)-(+)-Arginine-13C6) hydrochloride is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. |
|
| DC48526 |
Dihydromyristicin |
Dihydromyristicin, a plant flavonoid, has potent anti-inflammatory properties. Dihydromyristicin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. |
|
| DC48601 |
Clopirac |
Clopirac is a potent and orally active inhibitor of prostaglandin synthetase. Clopirac is an anti-inflammatory agent. |
|
| DC48640 |
Fusarochromanone |
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS). |
|
| DC48654 |
Benoxaprofen |
Benoxaprofen (LRCL 3794) is a potent and long-acting anti-inflammatory and antipyretic compound. Benoxaprofen is a relatively weak inhibitor of cyclooxygenase in in vitro systems, inhibits lipoxygenase in other systems, and inhibits monocyte migration in some animal models of inflammation. |
|
| DC48723 |
Tazofelone |
Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease. |
|
| DC48724 |
AXC-715 trihydrochloride
Featured
|
AXC-715 trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants. |
|
| DC48797 |
Ecabet |
Ecabet sodium (TA-2711) is currently applied to some clinical gastrointestinal disease by inhibiting the ROS production and improving Helicobacter pylori eradication. Ecabet sodium reduces apoptosis |
|
| DC49051 |
IL-17 modulator 5 |
IL-17 modulator 5 (compound 26) is a IL-17 inhibitor, with an IC50 of 1 nM. |
|
| DC49055 |
BRP-201 |
Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the treatment of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC50 value of 0.42 μM. |
|
| DC49130 |
PD-1/PD-L1-IN-23
Featured
|
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice. |
|
| DC49169 |
PD-1/PD-L1-IN-13 |
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8+ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model. |
|
| DC49218 |
L-Arginine-1,2-13C2 hydrochloride |
L-Arginine-1,2-13C2 ((S)-(+)-Arginine-1,2-13C2) hydrochloride is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. |
|
| DC49295 |
L-Arginine-1-13C hydrochloride |
L-Arginine-1-13C ((S)-(+)-Arginine-1-13C) hydrochloride is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. |
|
| DC49296 |
L-Arginine-13C hydrochloride |
L-Arginine-13C ((S)-(+)-Arginine-13C) hydrochloride is the 13C-labeled L-Arginine hydrochloride. L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis. |
|
| DC49341 |
Aminopicoline |
Aminopicoline (Ascensil) is a potent and nonselective inhibitor of NO synthase (NOS) isoenzymes (iNOS, nNOS, eNOS). |
|
| DC49356 |
7-Nitroindazole |
7-Nitroindazole is a selective nNOS inhibitor with antinociceptive and cardiovascular effects. 7-Nitroindazole is a useful tool to evaluate the biological roles of nitric oxide in the central nervous system. |
|
